CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

25 6 2025 05:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

11 6 2025 04:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

04 6 2025 04:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

28 5 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

08 5 2025 13:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

08 5 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

23 4 2025 13:08:12 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

09 4 2025 13:01:54 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

25 3 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

20 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

19 3 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

17 3 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

12 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 2 2025 05:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

13 1 2025 04:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 1 2025 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

18 12 2024 04:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

17 12 2024 13:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

04 12 2024 13:05:57 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

14 11 2024 07:01:00 提供 Nasdaq GlobeNewswire